

WHO WE ARE: MISSION & VISION

Rafael Pharmaceuticals is a privately held, clinical-stage, metabolic oncology therapeutics company.

- ❖ **Mission:** To develop highly selective, well tolerated, and highly effective anti-cancer agents, by selectively targeting altered metabolism in cancer cells. Our immediate goal is to improve the quality of life of patients with Pancreatic Cancer, which is the deadliest cancer worldwide and has limited treatment options
- ❖ **Vision:** Aspire to be a premier oncology company with primary focus to extend and enhance the lives of patients with difficult to treat cancers

ALTERED METABOLISM DIRECTED (AMD) PLATFORM

- ❖ Rafael's proprietary Altered Metabolism Directed (AMD) platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells
- ❖ Targets altered regulation of metabolic processes specific to cancer cells
- ❖ Highly specific, simultaneously attack multiple targets, minimally toxic and have broad spectrum activity across wide variety of cancers
- ❖ Potential therapeutic options for difficult to treat cancers
- ❖ Because of benign safety profile, devimistat can be used in chronic dosing and in combination with current standards of care with minimal added toxicity

CPI-613® (DEVIMISTAT) & PIPELINE


- ❖ Devimistat, our lead drug is currently being evaluated in two phase 3 trials in first-line metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML) in combination with standard drug therapy
- ❖ Over 500 patients to date spanning multiple tumor types have received devimistat in 21 ongoing or completed trials including 5 new trials (including 2 Phase III trials) as a single or combination therapy
- ❖ Devimistat has exhibited very good signal of efficacy and safety in phase I clinical trial data in various cancer indications:

Cancer Indication	Pancreatic Cancer	Acute Myeloid Leukemia (AML)	T-Cell Lymphoma
Treatment	devimistat + modified FOLFIRINOX	devimistat + cytarabine + mitoxantrone	devimistat + bendamustine
Patient Population	first-line metastatic	relapsed or refractory (≥60 years)	relapsed or refractory
Objective Response Rate	61%	52%	75%
Median Overall Survival (months)	19.9	10.4	9.2

- ❖ Devimistat has been granted US orphan drug designation for pancreatic cancer, AML, myelodysplastic syndromes (MDS), peripheral T-cell lymphoma and Burkitt's lymphoma. Devimistat also has orphan drug designation for pancreatic cancer and AML in the EU
- ❖ Novel chemical class, composition of matter and formulation protected until 2029 across US, Canada, EU, Australia, Israel and major markets of Asia (China, Hong Kong, Japan, South Korea, Taiwan)
- ❖ Several new drug/chemical entities (NCE's) targeting multiple tumor types are currently in discovery or preclinical stage

1 Duncan Drive, Cranbury, New Jersey 08512
Tel: (609) 409-7050; Fax: (609) 409 – 6035

SUSTAINABLE HORIZONS FOR GROWTH*



Phase 3 Pivotal Trials already recruited ~300 patients in pancreatic cancer and AML

20 Ongoing or Completed Clinical Trials in Multiple Hematological Malignancies & Solid Tumors

Rafael Pharmaceuticals entered into exclusive licensing agreement with Ono Pharmaceutical to accelerate clinical development and commercialization of devimistat in Japan and other Asian countries

EXPERIENCED LEADERSHIP TEAM

- Howard S. Jonas, *Chairman of the Board*
- Sanjeev Luther, *President & CEO*
- Robert G. L. Shorr, PhD, DIC *Chief Scientist/Co-founder*
- José Octávio Costa Filho, M.D., *Chief Medical Officer*
- Timothy S. Pardee, MD, PhD, *Co-Chief Medical Officer*
- Mike Hu, PhD, *Chief Development Officer*
- Wendy McDermott, *Chief People Officer*
- Paul Bingham PhD, *VP, Research*
- Rumin Zhang PhD, *VP, Discovery*
- Jehan Rowlands, Pharm D, *VP, Regulatory Affairs*
- Mike Stelmah, *VP, Manufacturing and CMC*

KEY ADVISORY BOARD MEMBERS

SCIENTIFIC ADVISORY BOARD:

- Chi Van Dang, MD, PhD
- Dafna Bar-Sagi, PhD

MEDICAL ADVISORY BOARD:

- Philip A. Philip, MD, PhD, FRCP
- Jorge Eduardo Cortes, MD
- Ariela Noy, MD
- Josep Taberero MD, PhD
- Eric Van Cutsem, MD, PhD